Results 2,141-2,160 of 3,759 for speaker:Pádraig O'Sullivan

Written Answers — Department of Employment Affairs and Social Protection: Social Welfare Payments (14 Jul 2022)

Pádraig O'Sullivan: 513. To ask the Minister for Employment Affairs and Social Protection the instruction that is given to local community welfare officers regarding the exceptional needs' payment (details supplied); the number of applications that have been received; the number of applications that have been approved; the overall amount of payouts that were approved in 2020, 2021 and to date in 2022; and if she...

Written Answers — Department of Employment Affairs and Social Protection: Employment Schemes (14 Jul 2022)

Pádraig O'Sullivan: 514. To ask the Minister for Employment Affairs and Social Protection if she is giving consideration to or is requesting her Government colleagues to consider allowing persons on various back-to-work schemes, employment schemes and other schemes to work a greater number of hours to entice them to remain in the workforce and provide for the economy; and if she will make a statement on the...

Written Answers — Department of Health: Medicinal Products (13 Jul 2022)

Pádraig O'Sullivan: 480. To ask the Minister for Health if his Department has completed the review of a report (details supplied) in respect of the drug reimbursement process; when this report and the key recommendations are expected to be published; the reason for the continued delay in publishing this report given that Covid-19 is no longer as large a public health risk as it once was; and if he will make a...

Written Answers — Department of Health: Medicinal Products (13 Jul 2022)

Pádraig O'Sullivan: 481. To ask the Minister for Health the reason that a report (details supplied) submitted to him in January 2020 at a cost of €86,000, has still not been published; if he will commit to prioritising its review and publication; and if he will make a statement on the matter. [38263/22]

Written Answers — Department of Health: Health Strategies (13 Jul 2022)

Pádraig O'Sullivan: 482. To ask the Minister for Health the status of the implementation of the key actions outlined in the National Rare Disease Plan 2014-2018; the timeline for the implementation of remaining actions; when a successor plan is to be published; and if he will make a statement on the matter. [38264/22]

Written Answers — Department of Health: Health Strategies (13 Jul 2022)

Pádraig O'Sullivan: 483. To ask the Minister for Health if his Department intends to follow through on the Programme for Government’s clear commitment to publish a successor plan to the National Rare Disease Plan 2014–2018; the reason for the delay in prioritising all remaining actions; and if he will make a statement on the matter. [38265/22]

Written Answers — Department of Health: Health Strategies (13 Jul 2022)

Pádraig O'Sullivan: 484. To ask the Minister for Health the work that has been carried out to prioritise the remaining actions in the National Rare Disease Plan 2014-2018; the deadlines for implementing these actions; the progress that has been made to date; and if he will make a statement on the matter. [38266/22]

Written Answers — Department of Health: Health Strategies (13 Jul 2022)

Pádraig O'Sullivan: 485. To ask the Minister for Health if a new liaison person within his Department has been appointed to oversee implementation of the National Rare Disease Plan; if a review conducted by the former liaison person will be published; and if he will make a statement on the matter. [38267/22]

Written Answers — Department of Health: Health Strategies (13 Jul 2022)

Pádraig O'Sullivan: 497. To ask the Minister for Health if a position has been identified within his Department that focuses solely on rare disease policy; if he plans to establish such a position for rare disease policy; and if he will make a statement on the matter. [38279/22]

Written Answers — Department of Health: Health Strategies (13 Jul 2022)

Pádraig O'Sullivan: 499. To ask the Minister for Health the status of all Programme for Government commitments to ensure an increased focus on rare diseases, as outlined in the Programme for Government; and if he will make a statement on the matter. [38281/22]

Written Answers — Department of Health: Legislative Measures (13 Jul 2022)

Pádraig O'Sullivan: 486. To ask the Minister for Health the extent of engagement that he has had with his Department officials on the Health (Pricing and Supply of Medical Goods) (Amendment) Private Members Bill 2021 that is due for Committee Stage; and if he will make a statement on the matter. [38268/22]

Written Answers — Department of Health: Medicinal Products (13 Jul 2022)

Pádraig O'Sullivan: 487. To ask the Minister for Health his views on the Health (Pricing and Supply of Medical Goods) (Amendment) Bill 2021; if he supports the proposed amendment to the Health Act; and if he will make a statement on the matter. [38269/22]

Written Answers — Department of Health: Medicinal Products (13 Jul 2022)

Pádraig O'Sullivan: 490. To ask the Minister for Health his plans to amend the Health Act 2007 to account for the unique context surrounding orphan medicinal products and advanced therapy medicinal products such as gene therapy; and if he will make a statement on the matter. [38272/22]

Written Answers — Department of Health: Medicinal Products (13 Jul 2022)

Pádraig O'Sullivan: 492. To ask the Minister for Health his plans to expedite the drug reimbursement process to account for the life-threatening nature of rare diseases; if he intends to make changes to the reimbursement process in Ireland that would enable expedited access for patients with severe unmet needs; and if he will make a statement on the matter. [38274/22]

Written Answers — Department of Health: Medicinal Products (13 Jul 2022)

Pádraig O'Sullivan: 495. To ask the Minister for Health his views on the continued use of the QALY threshold is respect of the drug reimbursement process; if his attention has been drawn to the negative consequences the use of the QALY as a cost-effectiveness tool can have on serving the unmet needs of rare disease patients; and if he will make a statement on the matter. [38277/22]

Written Answers — Department of Health: Medicinal Products (13 Jul 2022)

Pádraig O'Sullivan: 488. To ask the Minister for Health his plans to expedite the reimbursement process given that it currently takes, on average, 870 days for a patient to gain access to an EMA-approved orphan medicine in Ireland; the work his Department is doing in partnership with the HSE to ensure that this delay improves; and if he will make a statement on the matter. [38270/22]

Written Answers — Department of Health: Medicinal Products (13 Jul 2022)

Pádraig O'Sullivan: 489. To ask the Minister for Health if Ireland is currently in breach of the European Union Transparency Directive 89/105/EEC; if his Department intends to reduce the ongoing delays for patients to gain access to European Medicines Agency-approved medicine in Ireland; and if he will make a statement on the matter. [38271/22]

Written Answers — Department of Health: Medicinal Products (13 Jul 2022)

Pádraig O'Sullivan: 491. To ask the Minister for Health the work that is being carried out to enhance transparency and improve communication with patient groups and industry during the drug reimbursement process; if he will be open to providing a mechanism for patient groups and industry to establish communication with the HSE central processing unit throughout the reimbursement process; and if he will make a...

Written Answers — Department of Health: Medicinal Products (13 Jul 2022)

Pádraig O'Sullivan: 493. To ask the Minister for Health if his Department has examined international best practice such as in Scotland and Germany on the matter of interim and early access reimbursement models; and if he will make a statement on the matter. [38275/22]

Written Answers — Department of Health: Medicinal Products (13 Jul 2022)

Pádraig O'Sullivan: 494. To ask the Minister for Health the engagement he has had with his Department officials and HSE officials regarding the use of innovative payment models between industry and the State in respect of the drug reimbursement process for rare disease therapies; if he is open to such innovative solutions to ensure greater access; and if he will make a statement on the matter. [38276/22]